VALOR PRONÓSTICO DEL GLUTAMATO EN EL LÍQUIDO CEFALORRAQUÍDEO EN ESCLEROSIS MÚLTIPLE

PAPPOLLA, AGUSTIN; SÁNCHEZ FRANCISCO; PATRUCCO LILIANA; VARELA LUCIA; CASTAÑARES, CLARA NICOLE; LOPEZ, PABLO H. H.; CRISTIANO, EDGARDO; ROJAS JUAN IGNACIO

MEDICINA (BUENOS AIRES)

MEDICINA (BUENOS AIRES)

Lugar: Buenos Aires; Año: 2021 vol. 81 p. 774 - 779

0025-7680

Prognostic value of cerebrospinal fluid glutamate in multiple sclerosis. The objective of thisstudy was to evaluate the association between glutamate (Glu) levels in cerebrospinal fluid (CSF) atdisease onset and disease progression during follow up in a cohort of multiple sclerosis (MS) patients. Glu level was measured at disease onset (first relapse). MRI was obtained at baseline and follow-up (every 12 months) to determine the percent of brain volume change (PBVC), cortical thickness (CT), and T2 lesion volume (T2LV). The primary predictors of interest were baseline CSF Glu levels, PBVC and CT, as well as clinical disease progression [measured by Expanded Disability Status Scale (EDSS) and annualized relapse rate] during follow-up. A total of 26 MS patients were included. Mean concentration of Glu in CSF at diagnosis was 5.3 ± 0.4 µM/l. A significant association was observed between higher baseline levels of Glu and an increase in EDSS during follow up (b =1.06, 95%CI 0.47-1.66, p = 0.003) as well as PBVC (b = -0.71 95%CI -0.56-1.38, p = 0.002) and CT (b = -0.15, 95%CI -0.06-0.33, p = 0.01). We did not observe an association between baseline Glu levels and relapse rate or T2LV during follow-up (b = 0.08, 95%CI -0.11-0.43, p = 0.11 and b = 195, 95%CI -39-330, p = 0.22, respectively). Higher Glu concentrations at disease onset were associated with an increase in PBVC and EDSS progression during follow-up in MS patients.